Last updated: 2026-10-13 09:35:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Bio-Rad Laboratories, Inc. (BIO) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NYSE. The stock is currently priced at $364.53, with a market capitalisation of $9.79B and a P/E ratio of 43.81. Over the past 52 weeks, its price has ranged from $236.73 to $396.23. This page covers its latest market performance, valuation, price trends and company information.
$9.79B | |
$369.85 | |
$832.70 | |
$46.54 | |
$366.16 | |
132.48K | |
275.53K | |
43.81 | |
$396.23 | |
$236.73 | |
-- | |
-- |
Bio-Rad Laboratories, Inc. (BIO) is trading at $368.35 in pre-market trading as of 2026-10-12 23:31:00, up 0.60% ($2.19) from the previous close of $366.16
Pre-market trading shows how investors are pricing BIO before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Bio-Rad Laboratories, Inc. (BIO) moved from $369.14 to $364.53, representing a decline of 1.25% ($4.61).
The stock traded between $353.97 and $390.00 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 221.39 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 80.1%
BIO is currently trading at $364.53, placing it 80.1% of the way from its 52-week low of $236.73 to its 52-week high of $396.23. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees | 7450 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Bio-Rad Laboratories, Inc. (BIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.